drugset / Trial / NCT01665638

Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers

NCT01665638

Phase 1 Completed 10 enrolled Janssen-Cilag International NV
RandomizedCrossoverTriple-blind

Summary

The purpose of this study is to assess whether treatment with a single oral 300 mg dose of canagliflozin alters the kinetics (ie, clearance/removal from body) of serum C-peptide (a protein released from the pancreas during insulin secretion) in healthy adult volunteers.

Timeline

Start
2012-09
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral
Background HUMAN C-PEPTIDE Peptide 150 ug Intravenous
Background Somatostatin Traditional medicine (herbal / TCM) 500 ug Intravenous

Indications

No indication recorded.